Nitschke R, Smith E I, Shochat S, Altshuler G, Travers H, Shuster J J, Hayes F A, Patterson R, McWilliams N
Oklahoma University Health Sciences Center, Oklahoma City.
J Clin Oncol. 1988 Aug;6(8):1271-9. doi: 10.1200/JCO.1988.6.8.1271.
A prospective study was designed to evaluate the outcome of patients with localized resectable neuroblastoma without regional lymph node involvement when no therapy beyond surgical resection was administered. One hundred one patients observed for 3 to 60 months had a 2-year disease-free survival of 89% (SE = 5%). Of the nine patients experiencing relapse, only three have died. There were no apparent distinguishing characteristics of the nine failures. Due to the favorable prognosis of the subset of neuroblastoma patients, prognostic factor analysis had very limited power and lacked clinical importance. Complete gross removal of the localized tumors is adequate therapy to ensure the survival of the majority of these patients.
一项前瞻性研究旨在评估局限性可切除且无区域淋巴结受累的神经母细胞瘤患者，在未进行手术切除以外的治疗时的预后情况。101例患者接受了3至60个月的观察，其2年无病生存率为89%（标准误=5%）。在9例复发患者中，仅3例死亡。这9例治疗失败的患者没有明显的区别特征。由于该亚组神经母细胞瘤患者预后良好，预后因素分析的效能非常有限且缺乏临床重要性。对局限性肿瘤进行完整的肉眼切除是确保这些患者大多数存活的充分治疗方法。
